Intellia Therapeutics (NTLA)

Company Profile

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.

Company profile

Ticker

NTLA

Exchange

NASDAQ

Website

www.intelliatx.com

CEO

John Leonard

Incorporated

Delaware

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • QuidelOrtho • Idexx Laboratories • Myriad Genetics • Neogen • Lantheus • Meridian Bioscience • Celldex Therapeutics • Lucira Health • Achieve Life Sciences ...

SEC CIK

0001652130

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Intellia Securities Corp. ...

NTLA stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$81.73

Low target

$39.00

High target

$120.00

Latest filings (excl ownership)

View all

8-K

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug

2 Mar 23

S-8

Registration of securities for employees

23 Feb 23

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

23 Feb 23

8-K

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

5 Jan 23

8-K

Entry into a Material Definitive Agreement

1 Dec 22

424B5

Prospectus supplement for primary offering

1 Dec 22

8-K

Intellia Therapeutics Presents New Interim Data

14 Nov 22

8-K

Regulation FD Disclosure

3 Nov 22

Transcripts

View all

NTLA

Earnings call transcript

2022 Q4

23 Feb 23

NTLA

Earnings call transcript

2022 Q3

3 Nov 22

NTLA

Earnings call transcript

2022 Q2

4 Aug 22

NTLA

Earnings call transcript

2022 Q1

5 May 22

NTLA

Earnings call transcript

2021 Q4

24 Feb 22

NTLA

Earnings call transcript

2021 Q3

4 Nov 21

NTLA

Earnings call transcript

2021 Q2

5 Aug 21

NTLA

Earnings call transcript

2021 Q1

6 May 21

NTLA

Earnings call transcript

2020 Q4

25 Feb 21

NTLA

Earnings call transcript

2020 Q3

5 Nov 20

Latest ownership filings

View all

ARK Investment Management LLC

Financial summary

Financial statements Chart NTLA financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	535.46 mm	535.46 mm	535.46 mm	535.46 mm	535.46 mm	535.46 mm
Cash burn (monthly)	(no burn)	(no burn)	36.70 mm	38.18 mm	29.96 mm	27.77 mm
Cash used (since last report)	n/a	n/a	98.81 mm	102.81 mm	80.66 mm	74.79 mm
Cash remaining	n/a	n/a	436.65 mm	432.66 mm	454.80 mm	460.68 mm
Runway (months of cash)	n/a	n/a	11.9	11.3	15.2	16.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

NTLA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	300	317	-5.4%
Opened positions	53	50	+6.0%
Closed positions	70	32	+118.8%
Increased positions	114	108	+5.6%
Reduced positions	78	94	-17.0%

13F shares	Current	Prev Q	Change
Total value	2.72 tn	4.46 bn	+60937.9%
Total shares	91.97 mm	78.62 mm	+17.0%
Total puts	266.60 k	449.50 k	-40.7%
Total calls	486.00 k	702.30 k	-30.8%
Total put/call ratio	0.5	0.6	-14.3%

Largest owners	Shares	Value	Change
ARK Investment Management	9.42 mm	$328.69 bn	-2.4%
Vanguard	7.81 mm	$272.50 bn	+18.0%
BLK Blackrock	7.26 mm	$253.14 bn	+18.4%
CRBU Caribou Biosciences	4.55 mm	$0.00	0.0%
STT State Street	3.75 mm	$131.00 bn	NEW
REGN Regeneron Pharmaceuticals	3.70 mm	$437.84 mm	0.0%
Atlas Venture Fund IX	3.58 mm	$0.00	0.0%
CMTDF Sumitomo Mitsui Trust	2.98 mm	$103.83 bn	+0.4%
Nikko Asset Management Americas	2.98 mm	$103.74 bn	+0.4%
MS Morgan Stanley	2.52 mm	$87.86 bn	+64.5%

Largest transactions	Shares	Bought/sold	Change
STT State Street	3.75 mm	+3.75 mm	NEW
Wellington Management	1.99 mm	+1.42 mm	+246.6%
Vanguard	7.81 mm	+1.19 mm	+18.0%
BLK Blackrock	7.26 mm	+1.13 mm	+18.4%
MS Morgan Stanley	2.52 mm	+987.60 k	+64.5%
Norges Bank	857.28 k	+857.28 k	NEW
Citadel Advisors	1.20 mm	+641.55 k	+115.2%
FHI Federated Hermes	2.11 mm	+592.05 k	+39.1%
Rokos Capital Management	826.06 k	+535.54 k	+184.3%
Deep Track Capital	700.00 k	+400.00 k	+133.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NTLA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Mar 23	Basta James	Common Stock	Sell	Dispose S	No	No	43.88	1,088	47.74 k	55,279
1 Mar 23	Basta James	Common Stock	Grant	Acquire A	No	No	0	12,269	0.00	56,367
1 Mar 23	Basta James	Common Stock	Grant	Acquire A	No	No	0	24,539	0.00	44,098
1 Mar 23	Basta James	Stock Option Common Stock	Grant	Acquire A	No	No	40.75	34,674	1.41 mm	34,674
1 Mar 23	Eliana Clark	Common Stock	Grant	Acquire A	No	No	0	6,134	0.00	45,146
1 Mar 23	Eliana Clark	Common Stock	Grant	Acquire A	No	No	0	24,539	0.00	39,012
1 Mar 23	Eliana Clark	Stock Option Common Stock	Grant	Acquire A	No	No	40.75	34,674	1.41 mm	34,674
1 Mar 23	Laura Sepp-Lorenzino	Common Stock	Grant	Acquire A	No	No	0	29,938	0.00	47,567
1 Mar 23	Laura Sepp-Lorenzino	Stock Option Common Stock	Grant	Acquire A	No	No	40.75	42,302	1.72 mm	42,302
1 Mar 23	David Lebwohl	Common Stock	Grant	Acquire A	No	No	0	30,674	0.00	56,361